Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are often refractory to existing antiepileptic medications. Therefore, there is an unmet need for better seizure control, which could potentially improve other symptomatic domains such as cognitive function.
INTRODUCTION
Deletions or mutations of the maternally inherited copy of the UBE3A gene cause Angelman syndrome (AS). Individuals with AS exhibit developmental delay, motor dysfunction, minimal speech, highly penetrant EEG abnormalities, and seizures (1, 2) . Epilepsy in AS is common (80%-95%), polymorphic, and often resistant to available antiepileptics. The frequency, severity, and pharmacological intractability of the seizures exacts a heavy toll on individuals with AS and their caregivers (3) (4) (5) (6) . AS model mice lacking a functional maternal copy of the orthologous Ube3a gene (Ube3a m-/p+ ) phenocopy many clinical aspects of AS, including seizure susceptibility and EEG abnormalities, thereby offering a preclinical model for developing new therapeutics (7) (8) (9) (10) (11) (12) (13) (14) (15) .
Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, is gaining attention for its antiepileptic, anxiolytic, and antipsychotic properties (16) . In 2018, the FDA approved CBD (Epidiolex ® ) for the treatment of seizures associated with two rare and severe forms of epilepsy -Lennox-Gastaut syndrome and Dravet syndrome. While the interest and off-label medical use of CBD has largely outpaced the preclinical and clinical research, CBD may provide a viable treatment for several other neurological disorders associated with epilepsy such as AS (17) (18) (19) (20) . However, little is known about the potential antiepileptic and other benefits of CBD in AS. The broad beneficial spectrum of CBD makes it a unique candidate for treating the complex symptoms associated with AS, as it holds the potential to simultaneously ameliorate behavioral deficits, EEG abnormalities, and seizures (21) .
In this study, we systematically tested the beneficial effects of CBD on core AS-related pathologies in mice, with the expectation that this information will guide eventual clinical use. We report that acute treatment of CBD substantially attenuated audiogenic and hyperthermia-induced seizure severity, and normalized delta rhythms in AS model mice. The anticonvulsant dose of CBD (100 mg/kg) caused mild sedation, but had little effect on motor coordination or balance. While acute CBD could suppress seizure severity, CBD stopped short of being able to prevent the proepileptogenic plasticity observed in AS model mice. Our study provides a preclinical framework to better guide the rational development of CBD as an AS treatment.
RESULTS & DISCUSSION
As with individuals with AS, mice with maternal loss of Ube3a exhibit epileptic phenotypes. For example, AS mice on a 129 background have elevated seizure responses to acoustic stimuli (9, 10, 14) . We verified that AS model mice (129 background) exhibited more frequent audiogenic seizures than wild-type (WT) littermates and had a far greater likelihood of progressing from wild running to a more severe tonic-clonic episode ( Figure 1 ). Acute treatment of CBD at higher doses significantly reduced the frequency (@ 100 mg/kg CBD) and severity (@ 50 and 100 mg/kg CBD) of audiogenicinduced seizures ( Figure 1 ). These results suggest strong dose-dependent anticonvulsant effects of CBD in AS model mice.
We recently implemented the flurothyl kindling and retest paradigm in AS model mice (C57BL/6J background), and found that AS model mice responded to both initial (day1) seizure induction and kindling (day1 -day8) similarly to WT mice, but they displayed a markedly increased sensitivity to flurothyl-induced seizure measured a month later at retest (day36) (8) . Elevation of core body temperature also triggered convulsions in kindled AS but not WT mice, resembling the clinical observation that AS individuals are susceptible to febrile seizures with moderate increases in body temperature (3, 4, 8) . To test whether the anticonvulsant effects of CBD are generalizable across different seizure induction paradigms, we treated flurothyl-kindled mice acutely with CBD (100 mg/kg) 1 hr prior to the flurothyl-or hyperthermia-stimuli ( Figure 2A) . Surprisingly, the acute administration of Figures 1D and 1E ), suggesting that two-week long CBD treatments (at 100 mg/kg) cannot prevent the pro-epileptogenic plasticity that occurs following kindling in AS mice.
Motor and behavioral impairments are common in AS children, significantly impact their daily lives, and increase the burden of their caregivers. No effective drug treatments are available. AS model mice exhibit behavioral and motor deficits (7, 9, 15, 22) , some of which resemble those observed in AS individuals. To explore possible behavioral benefits of CBD, we treated AS model mice and WT controls with various doses of CBD 1 hr prior to behavioral testing. Similar to prior observations (7, 9, 15, 22) , we found that vehicle-treated AS model mice exhibit impaired locomotor 6 activity, poor motor coordination, and reduced marble burying behavior (Figure 3 ). Open field activity was reduced in AS model mice, and CBD had a dose-dependent sedative effect in both WT and AS mice ( Figures 3A and 3B ). Consistent with previous findings in rats (23) , CBD did not have a major impact on motor skill learning and memory, regardless of genotype, as measured in rotarod acquisition and retest ( Figures 3C and 3D) . Notably, CBD at 100 mg/kg exaggerated the marble burying deficits of AS model mice ( Figure 3E ), which might be a consequence of its sedative effects.
AS individuals have higher EEG power across all frequencies compared to neurotypical controls, with the largest difference manifested in a prominent peak in the delta frequency range (13, (24) (25) (26) . Electrophysiological recordings from freely roaming AS model mice suggest strain-and region-dependent quantitative differences in EEG power spectrum analysis -the most robust elevations of delta and theta power were found in cortex of AS mice on a C57BL/6J background regardless of light cycle (7) . Here we monitored and quantified cortical local field potentials (LFPs) of freely roaming AS and WT mice (C57BL/6J) after a 2-week vehicle or CBD treatment (Figure 4 ).
Consistent with previous findings (7) , AS model mice exhibited enhanced electrophysiological power compared to WT mice, particularly in delta (1-4 Hz) and theta (5-8 Hz) activity. CBD treatments had little effect on LFP power in WT mice, whereas the treatment significantly lowered total LFP power, including both delta and theta activity in AS model mice, normalizing levels to those observed in WT mice (Figure 4 ). All mice showed similar weight gain over the two weeks regardless of genotype and treatment (Supplemental Figure 2 ).
Our data are the first to show that CBD can reduce both acoustically-and hypertherimia-induced seizure severity in AS model mice. As such, our findings suggest that CBD might attenuate seizures in AS individuals, which expands the therapeutic spectrum of the anti-epileptic effects of CBD (17, 19, 23, (27) (28) (29) (30) (31) (32) . The fact that neither acute nor chronic post-kindling CBD treatment affected flurothyl-or 7 hyperthermia-induced seizure threshold in AS model mice suggests that further evaluation of CBD using additional models of epilepsy is required to reveal the full antiepileptic potential of CBD in AS.
The context-dependent antiepileptic effects of CBD suggest that different seizure models can engage distinct mechanisms for seizure initiation and propagation. And, relevant to human use, such a finding indicates that CBD might be beneficial for some types of seizures and not others, depending on the circuits engaged and/or at what stage of epilepsy intervention begins.
CBD shows behavioral benefits in animal models of motor, social, and cognitive impairments (33) (34) (35) (36) (37) . However, the behavioral benefits of CBD in animal models often exhibit an inverted Ushaped dose-response curve, with higher doses (> 20 mg/kg) being ineffective and sedative, whereas lower doses can prove effective (38, 39) . This conundrum for designing CBD dosing that both control seizures and improve behavior was also found in studies of Dravet syndrome model mice (40). The same may be true for AS, as the effective concentration (e.g. 100 mg/kg) at which we observed anticonvulsant effects also produced sedative effects. Notably, the sedative effects in mice at higher doses of CBD preclude meaningful interpretation of many movement dependent behavioral paradigms (e.g. 3 chamber sociability test, fear-conditioning, and Morris water maze), and may also explain the reduced marble burying behavior, which is associated with locomotor activity (41) .
However, while AS model mice recapitulate many AS-like behaviors, activity is not one of those; AS model mice are hypoactive, while AS individuals are often hyperactive (42) . Thus, while anticonvulsant doses of CBD (i.e. 100 mg/kg) are mildly sedative in AS model mice, it is conceivable that analogous CBD dosing could alleviate hypermotor behavior often observed in AS individuals. EEG power is broadly increased in children with AS relative to age-matched neurotypical controls, and this is recapitulated under certain conditions in AS model mice relative to WT littermates (7, 24) . Among the elevated EEG spectrum, enhanced delta rhythm is a particularly reliable biomarker for AS (13) . Here we found that two weeks of CBD administrations reduced wide spectral cortical electrophysiological activities, and normalized the delta (1-4 Hz) and theta (5) (6) (7) (8) This study lends critical support for using CBD to treat seizures, along with behavioral and EEG abnormalities in AS, and expands the potential beneficial spectrum of CBD. 
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